Identification of genes with higher expression in human uterine leiomyomas than in the corresponding myometrium

In: Molecular Human Reproduction · 2002 · vol. 8(3) , pp. 246–254 · doi:10.1093/molehr/8.3.246 · PMID:11870232 · W2099614758
article OA: bronze CC0 ⤵ 1 in-corpus citation
AI-generated summary by claude@2026-06, 2026-06-13

Representational difference analysis identified increased expression of PAPPA, tomoregulin, CRABP1, ZFP 185, and LTBP2 in human uterine leiomyomas compared to myometrium, suggesting novel molecular mechanisms for leiomyoma growth.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We used a PCR-based subtraction method, representational difference analysis of cDNA (cDNA--RDA), to identify genes with a higher expression in leiomyomas in comparison with the corresponding myometrium during the proliferative phase of the menstrual cycle. Increased expression of the genes for pregnancy-associated plasma protein A (PAPPA), tomoregulin, cellular retinoid acid binding protein 1 (CRABP1), zinc finger protein 185 (ZFP 185) and latent transforming growth factor beta binding protein 2 (LTBP2) was demonstrated in individual leiomyoma samples compared with corresponding myometrium. Additionally, a specific positive immunostaining of LTBP2 was found in the smooth muscle cells of both leiomyomas and myometrium. These genes may be part of previously unidentified molecular mechanisms responsible for the selective growth advantage of leiomyomas compared with myometrium. This work expands our knowledge about the molecular nature of leiomyomas and provides novel candidate genes to further explore in relation to their function during leiomyoma growth.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Cited by (1)

References (66)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK